Clinical Analysis of Neuroblastoma by 최승훈
=Abstract= 
Clinical Analysis of Neuroblastoma 
Tae Jin Kim, M.D., Seung Hoon Choi, M.D., Eui Ho Hwang, M.D. 
Division of Pediatric Surgery, Yonsei University College of Medicine 
Seoul, Korea 
Neuroblastoma is a solid tumor derived from neural crest cells of the sympathetic 
nervous system. It is the most common extracranial solid tumor in children. Although 
it has the highest rate of spontaneous regression, it has a bad prognosis. Recent 
reports indicate a much improved outcomes utilizing the multitreatment approaches 
and early diagnosis as a result of patient screening. We have studied 42 patients 
managed in the last decade at the Severance and Y ongdong Severance Hospitals. The 
patients were followed until January 1998 and analyzed in terms of age, sex, 
admission period, stage, diagnostic studies, clinical symptoms, physical findings, oper-
ative time, treatment modalities, and survival rate. Twenty eight patients underwent 
operative procedures, 16 patients had postoperative chemotherapy, and 19 patients 
had preoperative chemotherapy. Sexual difference was 1.33:1 in favor of males, and 
43 % of patients were under one year of age. The patients were initially diagnosed as 
a result of symptoms and signs. An abdominal mass was the most common clinical 
finding. Eighty six percent of the patients were in advanced stages (>Stage III of 
INSS). The 2 year survival rate was 59.2 % and the 5 year survival rate was 29.6 %. 
Index Words: Neuroblastoma, Chemotherapy 
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Table 1. Single or Combination Chemotherapy 
of Preoperative Period 
Regimen Number of cases 
VP 16 3 
VP 16. ADR 3 
VP16. ADR. CDDP 3 
ADR. CDDP 2 
VP16. CTX. DEXA 1 
VCR. CTX. EPI. CDDP 1 
VCR.ADR. CTX 1 
VP16. EPI. CDDP 1 
VCR. CTX 1 
VP16. EPI. CDDP 1 
CTX.ADR. CDDP 1 
ADR: adriamycin. CDDP: cis- platinum. CTX: 
cytoxan. DEXA: dexamethasone 
EPI : epirubicin. VCR: vincristine 
6. ~71 
~A~]-lE-*~(INSS)oJ] uj-~ ~ 7] -c stage 10] 2 
il11, stage IlIo] 9il11, stage IV7} 27il1] ~Jl stage II 
.2} stage IV -S ~ iii ~ q. stage IV oJjJ'l ;~Jo ]-¥-5f1-c 
bone 0] 17il1]£ 7}7-J ~~Jl, lung 8il11, brain 2il1] 
';0] ~~q. 
"T-~~ §j-"§:j-R~.g. 19i11joJP'1 A}%"6"}~ Jl VPI6 
t!~ .tE-c *~~£ A}%~ 7cH-7} 7}7-J ~~~oj 
(lE I), "T-~ + §j-"§:j-R~ ::'. 16il1joJj Al A}%"6"}~~oj 
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-"j ii~~.g. :@7.}-c 2L9±9~, ~%R'il % ~.g. :@7.} 
-c 21.3 ± 14.7 ~£ -'j'- -;;:- -D-oJj j,}0]7} 'iiJ~q. 
8. ~IE ~.il~2~ ()jl~ 
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;'~ ~ "6"}~ Jl 14il1j 7} A}{]J"6"}~q. 31;:3. O] AJ ;.~~~ 
:@ 7.}-c II il1j ~ ~ oj 51;:3. oj AJ ;.~ e ~ 7Cl-'f--c 8 il1j 
£ Al 51;:3. ;.~e%.g. 29.6%~Jl 21;:3. ;.~~%.g. 
59.2 % ~~oj :;JeTI' ;.~e7j-D-.g. 3.31;:3.0]~q. p},A] 
~~£ 3':-"H! 7Cl-'f-oJj ~:@oJj rJ1~ 7aA} ~ S'..-'j'-
Table 2. Combination Chemotherapy of Posto-
perative Period 
Regimen Number of 
cases 
VP 16. ADR . CDDP 3 
VP16.ADR 3 
VP16. CTX. CDDP 3 
VP16. CTX. ADR. CDDP 2 
VP16. EPI. CDDP 1 
VCR. CTX.ADR 1 
VCR. CTX. EPI. DTIC. CDDP 1 
VCR. CTX.DCB 1 
ACR. CTX. VCR.CDDP 1 
ADR : adriamycin. CDDP: cis- platinum. CT 
X : cytoxan. DEXA : dexamethasone 
EPI : epirubicin. VCR: vincristine. DCB: 
dacarbazine 
4 Y r 5 Y r 
Fig. 1. Actual survival of patients with neuroblastoma after surgery. 
- 60 -
A]"E i5}?] CJ:- i5}o:j 0] %-f':- disease free survival 0] 
o].\-:! 1(1--i? "'H':·7] Zlo]9ic.].p 'tl I). 
{! 7(j .2.l-i] ± %-f':- 1:l].iiL~ '?1'Z1 ~"'E i5}-c ~:@-.Q. 
£ 2"'i] o]Y1cJ] 60% 7} ~"!li5}Jl lO"'i] o] Y1cJ]-c 
97 % 7} ~"!l ~q.Jl i5}1Jj 6, Ai ?}9.] 7(j q-cJ]-c Pi] 
0] ~o] 43 %, 10"'1] 0] ~o] 95 %£ 0] ~l- l:l] ~~ 
~±~ 5!.'X1,c.} . "!l-"-1 1(1-11] ~ t+-'T- -c ~*liJcJ]-c 
(staging system) q g:il} ~-f':- "'i]7]'?'] 7]' 9) q. Ch-
ildren 's cancer 'study groupcJ] Ai 0.Jl ~,-c Evans 
~*1iJ (CCS Stage)Jl} St. Jude children 's research 
hospital :il} pediatric oncology groupcJ] J..i 0.-c ~ 
*1iJ (POG Stage)~ TNM ~*7} ~q. £1~cJ]-c 
0]% ~ %~~ ~Ai] ~*IiJ(INSS)I,7% Ll1-i'-~ M 
.Jl ~q. J..}q-q o}2}l:l]o}cJjJ,i-c Stage II 30%, 
Stage III 30 %, Stage IV 35 %, Stage IV -S 5 % 2} 
Jl 5!..Jli5}o:j AiA}~-"-1 7(jq-~ 7JO] Stage III~ 
Stage IV-"-1 :@-?}7} fl'V:.Q. t+ ~3.2.] 'cl 0] 5!..!f1:§} 
~oj ~-c '?1~ ~cJ]J..i-c Stage III, IV.9.j :@-A}7} 
3j.Jl Stage I, II, IV-S :@-;:<.}.9.j l:l] %0] itq 8. ~ 
5:A l-cJ] J..i ';3-1..'j TAd l:l]-c 1.33: 1 0]9i.Q. oj, "T ~ 
AJJl} 0 ] ~3j ~{!-f':- *-i'- %:il] 7} <>Js:.3j.Q.£ fl 
'V:q. "T~ Ci:VJ~AJ 2..£ *-i'-%JI17} 7};<.J ~i5} 
Jl ~ ~ -i'-ill cJ] at2}J..i qOJ~ ~AJO] t+E.j-t+oj, 
!'E~ ~o]cJ] -"-1~ ~AJs:. ~1(1-'it""]cJ] 60-80%cJ] 
0]2-c ?;!..Q.£ 7]~SO].Jl ~.Q. oj 0]'3' ~'T- ~o] 
cJ] -"-1~ ~, -tl-~% 0] 7]·;<.J ~~ ?;!..Q.£ 7]~~ 
Jl ~qi,3,4,9. ~l(!-"-1 VMA (vanillylmandelic acid) 
~ HVA(homovanillic acid)7} 90 %cJ] J..i AJ%~ oj 
~2..oj, ~~cl ferritin , neuron-specific enolase, LDH 
~-f':- "!l-"-1 ~i5PJs:., oj]+~ o}-cLl] %Jl7} SO].Jl 
~Jql,9 ~1(1-3j ~J..}£-c *-i'- 7',:l#Ei 1(1-"8'- ~Od 
:ilL ..B..'3' VMA, HVA 7,3J..j-7} 7};<.J *%i5}~tj 
?;!. ~ ~ 'T- ~q. N-myc *~?}-"-1 7,:lJ..}7} 3j9i 
tj ?;!.::: °pllJ}?] o]cJ] Ll1~ 7,:lJ..}7]· 11?] U'V: 
gcJ] 7]~i5}::::r~] N-myc *~?}-"-1 ~~o] oj]+cJ] 
'?l ~ i5} 71] -tl-o:j i5}:::: ?;!':il} 0] ~ 0] % ~ j.] lis:. ~ 
2}~E£ ~.Q.£-C £~ :@-4~~ ~'~o:j~ 
w ~ ..B..7} ~ q. *-i'- 1(1-"8'-~od.g. ~ 1(1-¥-0} 1-] 2} 
"!l7]-"-1 ~*cJ] s:. *%i5}o:j j.]li t1JIiJ -"-1 ~:AJ cJ] 
j.] -C :;i2..£-c "!l 7], ~1(1-A] :@-?}-"-1 t+ 0]¥-0}1-] 
2} ploidy, Shimada "!l7], N-rnyc fr~?}%-~, ~ 
~cl ferritin ~o] ~-c r~] o]'3'cJ]J..i£ "!l7], t+ 0], 
N-myc %-~o] 7};<.J '3'..B..~ ~ w% ~qlO. Stage 
IV-S~ ~lA-"-1 "'~ ~% £ diploid, N-myc *~;:<.}, 
Unfavorable histology %cJ] at 2Pi q..soj 27H-%! 
O] AJ JI1 0]i5}~ 7(jq- cJ]s:. "'~~%o] ~",*qII 
{! 1il £"'1] ± %::: 1970\1 rlllJ};:<'] ~ i5}Li4 s:. 2\1 
",~~%o] o] ';::-cJ]J..i-c 32%, '?1~cJ] J..i-c 29 %4 
Jl 5!..Jl~ oj]+ 7} uHq- t+~ %oJo]9i2..t+, a,]~ 
-"-1 qOJ~ j.] li t1JIiJ -"-1 ~~ £ oj] +7} %,-0};>;].Jl 
~c.}12. j.]li-"-1 t1JIiJs:. :@-?}-"-1 t+0]~ N-myc * 
~ 7j--"-1 ~~, Shimada -"-1 "!l2.]~:§}, ~~cl ferritin 
cJ] at 4J..i ~ C1 i5}o:j %'-::: ~ Jl} ~ ~ ~ 'T- ~ -c r~] 
ill~£7} 3j::: :@-7}-i:!'-cJ]J..i-c CCSG-388l%, ill~ 
s:.7} it::: :@-;:<.]·-i:!'-cJ]J..i:::: CCSG-389l-"-1 ~%j.] li 
~ 3j %i5}o:j ill ~ £7} ,;;!--f':- :@-;:<.}-c 4\1 z} "'~ ~ 
%0] 100 %, Pi]o]i5}o];>;]~ ~7}?] o] ""J-"-1 ill~ 
~?}7} ~-c :@-?}-c 90%, Pi] 0] ""Jo] oj ill~~7} 
7} ~-c :@-;:<.}-c 54 %~qlO. a,J-2-o1]-c Stage IV.9.j 
:@-7}cJ]J..i ~'T-0]~¥- 0}1-]4 ~~~z}Ai] ±o]~ 
~(PBSCT)~ o]%i5}o:j ~.g. ~Jl}~ ~9iq.Jl 5!. 
.Jlso]-cr~l, Eguchi ~-f':- IV 7 ]-"-1 {!7(j£A~]±%:@-
7}cJ] J..i carboplatinum, VP-16, melphalan ~ ~ ~ 
o:j i5}.Jl ~ ~ ~ z} Al] C'f 0] ~ ~ %""] cJ] ",,] i5~ -t;}o:j 13 
ua '3' 5ua 0] ~~ {!-iiH ~ 7ua '3' 2ua 0] -i'-~{!-iiH ~ 
~.g. ?;!.2..£ 5!.Jli5}~ql3. ~%..B..liJcJ]s:. fl::: 
~~o] ~oj a,J-2-cJ]-c DNA-topoisomerase I inhi-
bitor~ irinotecan(CPT-ll)o] 12f-%! ~ It:il}~ 5!. "?:l 
0] %%~~.ll} 0dAJ~TcJ]J..i ~ua SO]9iqI4, 15 ~ 
i5~~ "!l7]-"-1 {!7(j£"'l]C'f%cJ]J..i:::: 691cJ] J..i 891cJ] 
7~ {l ~%j.]li+ 'T-~'3' t1JJ..}{!..B..1iJ ~ %~ -t;}o:j 
~ ~"!l ~~ "?:l Ilj-{! % Al]71-t;}o:j 63 %-"-1 %,-.g. "'~ 
~% ~ ~ ~ 'T- ~2..E£ 3j ~~ ~ 'T-~ j.] li7} 
~..B..i5}q I 6,17. 'T-~'3' llJJ..}{!..B..IiJ::: lOOOcGY -"-1 
5:J..}~ -t;}-c ?;!.o] '?1~3j2..£ o]?;!.::: 91-i'-llJJ..} 
{! j.]li""] 3000cGY ~ 5:J..}i5}-c ?;!.:il} it::: ltJl} 
~ ~~ T ~JqJl ~q. Stage III 0] i5}-"-1 :@A 
cJ] J..i -c It.ll}~ 5!.?] ~ Stage IV :@-;:<.l-cJ] J..i -c "'~ ~ 
%0] 30%£ .=Iq;>;] ~;>;] Uq l8 o]91cJ]s:. re-
tinoic acid~ angiostatic agent~ TNP-4700] Al] C'f 
- 61 -
~.* *~~~~ %~£~~ .~~ ~~~ 
j,] li o1] RJl}7} ;Uq~ .Jil..Jl 7]- ;U q I9,20 l31I-
Metaiodobenzyulguanidine( 13II-MIBG)* 0] %ii}~ 
~~£~~%~ Jl%~~ ~4~~4* *£~ 
Ii':! ~ i>~~ ~ 7] * 7}~ ~7.} 01] },~ ~ 50 % ~s=.~ 
j,]li1L4* ~~ ;Uq21. ~~.£},~] ~%~ j,] li~ 
j,] t-01] ~ N-myc oncogene amplification, Chromo-
some Ip %~ Chromosome structural abnonnality, 
Ha-ras p21 protein~ ~ 7}~ lE ~:il}, Shimada cl-
assification ~ unfavorable histology type %~ ~ 
~ oj] ~«l7.} 9) '7t ~ ~ ~ , ~7] ~ 7] (I, II , IV -S), 
Favorable DNA ploidy ;= ~ ~,g. oj] ~«l7.} 9} 
ferritin , NSE, LDH ;=~ %0J: lE «l 7.}~ ~7} ~ 
£01] u:te} j,] li<lJ~o] ~~so] ~ 7;3~0]ql,2, 12,22 . 
~~~~~~~ ~~:il} .Jil..~R~ ~ ~~~~ 
7;3i>J:0 ] ;U£oj, Jl~]~ ~ o1JA~ ~ o] ~~ .~R~ 
4 <lJ},}{iR~ 0] 4-7}~ q . ~ B "itA] {J ~ ~ ~ 
7} ~£Ii':! ~~ .~R~ ~ ~~o] A] i>~ ~Jl 
;U£oj, ~~~ Al]~5O] .A] *~ %0J:~ <lJ},}{i j,] 
li * A] i>~ ii}~ ~ ~~ 0] -61 ~ tumor specific 
antibody ~ retinoic acid 7} },}%50] 7] £ ~q. 
~ ~To1] },~~ ~AJ~~ ~ ~t!0] ~ 7;3~~ 
2\1 },~ ~%o] 59.2 %, 5 \1 ),~ ~%o] 29.6 % ~ 
ojl~7} 7.~~ii};1.Jl, °l~ 1J.l] °l ~ ~B-'8 7;3~ 
7} 57 %~ '\1':U-71 u:j]-lf-0]Jl EE~ ~B eJA]91 
Stage III 0] AJo] 95 % 0] AJo] ~U] u:j] -If- 0] e} Jl ),~ 
z.t ~~ ;Uq. 1J.l] o]AJo1] },~ ~ ~,g. ~ 7]~ ojl ~ 
~ u~~ ~~~ 20 %~s:.e}Jl .Jil..Jlso]Jl ;U q l,23. 
Bessh04~ .Jil...Jl.so} Woods24 ;= El .Jil...Jlo1]}'i .Jil..qA] 
lIj j,]t-01] ~ ~~, *olo1] },~ VMA spot test.so}, 
VMA, HV A~ High perfonnance liquid chromato-
graphy ;= £~, ),~~ 67H-%! ~ °d 0}01] tJ1'iiH ~ 
3..c1'<1 ~ .A] i;~'ii}~ ~7101] ~{!i>H},~ j,]liW£~ 
},~ 95 %0]AJ~ ~~ j,l li%4 ~71 ~ 71 ~B% 
4 ~~ ~B%(1f7000-1/15000) ~ ~Jl ;Uq2. 0] 
.so} :Q-~ ~~~~ ~71~B4 ~3.. c1'<1 ~ ~ii} 
~ ~-2'>] j,]li ~ .A] 3}w£~~i 1:1"* ~~ oj]~~ 
~~~ ;U~ ~o]q. 
},1] ~%01] ~ii}04 ~~, )'j ~ ~~, ~ 71, ~ B '3J 
j,] li, ),~ ~% 01] tJ1'ii}~ .Jil..Jl ii};1. q. ~ 7] ~~01] 
},~ ~ ~~-:ii-01] },~ .Jil..Jl -'8 ~01] 1:I] ii}~ Stage IlI.so} 
Stage 1V~ 1:1] %0] ~Jl °]01] u:te}},~ ),~~%£ 
7.1 ~ii}~ q. u:t2.}}'i ~7]~t!:il} ~7] j,] li* 7] ii} 
~ },~ ~%~ ~ii]~ Ll] 9-?::jii}~ o): ii}oj, N-myc 
*~ 7.}~ ~~ %% 7,3},} 'ii}~ oj] ~~ 3ll-~4 j,] 
li~ T~~}* 7] 'ii} ~ ~s:. ~Rii}q. ~%R~ 
0] ~ 01] £ ~ c1 7}7.] j,]li ~ 0] A] s:.~ Jl ;U ~ ~ 
A] ~ o1] Ai -:ii-Y101]Ai2.}£ ~%R~~ %~Jl} j,] li 
llJ{J % ~ii}~ ~o] ~R~ u:j] 7}so]Di, ~cl tJ1~ 
Zl-~ %<>J~ llJ{Jo1] u:t2.} ~7.}* ~*ii}Jl j,] li 
ii}~ ~o] ~Rii}qJl ),~z.t-'8q. 
1. %::<J§j: %::<J§j ~o}Jl}(ed 6). 1997, Pp 913- 916 
2. Katzenstein HM, Cohn SL: Advances in the 
diagnosis and treatment of neuroblastoma. Curr 
Opin Oncol 10(1):43-51 , 1998 
3. Marina NM: Diagnosis and treatment of the 
most common solid tumors in childhood. Ca-
ncer Diag Treat 19(4), 871-889, 1992 
4. Bessho F: Colloquy on neuroblastoma scre-
ening. Med Pediatr Oncol 31(2):106-110, 1998 
5. Matthay KK: Neuroblastoma, biology and th-
erapy. Oncology 11(12):1857-66, 1997 
6. Matthay KK, Perez C, Seeger RC, Brodeur 
GM, Shimada H, Atkinson lB, Black CT, 
Gerbing R, Hasse GM, Stram DO, swift P, 
Lukens IN: Successful treatment of stage III 
neuroblastoma based on prospective biologic 
staging; a Children's Cancer Group Study. J 
Clin Oncol 16(4):1256-64, 1998 
7. Brodeur GM, Pritchard J, Berthold F, Carlsen 
NL, Castel V, Castel berry RP De Bernardi B, 
Evans AE, Favrot M, Hedborg Fl: Revision of 
the International Criteria for Neuroblastoma, 
J Clin Oncol 11(8):1466-1477,1993 
8. al-Mulhim I: Neuroblastoma in children a 
IO-year experience in Saudi Arabia. J Trop 
Pediatr 44(2):77-80, 1998 
- 62 -
9. Grazia E, Cimador M, Bernardi B: Recent 
advances on retroperitoneal neuroblastoma. 
Arch Hal Urol Androl 69(4): 233-40, 1997 
10. Marina NM: Biology and treatment of pe-
diatric malignant solid tumors. Cancer Che-
mother BioI Res Modif 17:642-671, 1997 
11. Katzenstein HM, Bowman LC, Brodeur GM, 
Thorner PS, Joshi W, Smith El, Look AT, 
Rowe ST, Nash MB, Holbrook T, Alvarado C, 
Rao PV, Castleberry RP, Cohn SL: Prognostic 
significance of age, MYCN oncogene ampli-
fication, tuinor cell ploidy, and histology in 
110 infants with stage D(S) neuroblastoma: the 
pediatric oncology group experience-a pediatric 
oncology group study. J Clin Oncol 16(6):2007 
-2017, 1998 
12. Sawada T, Komatsu H, Shirai C, Yamamoto 
S, Ishiwari K, Ishida H, Olunizono Y, Ma-
tsumura T: Neuroblastoma. Japan J Cancer and 
Chemother 22(1):28-36, 1995 
13. Eguchi H, Takaue Y, Kawano Y, Watanabe 
A, Watanabe T, Kikuta A, Koizumi S, Ma-
tsumura T, Sawada A, Horikoshi Y, Sekine Y, 
Koyama T, Shimokawa T, Shimizu K, Ka-
wasaki K, Mugishima H, Takayama J, Ohira 
M, Ogawa M: Peripheral blood stem cell 
autografts for the treatment of children over 1 
year old with stage IV neuroblastoma: a 
long-terrn follow-up. Bone Marr Transpl 21 (10) 
:1001-1004, 1998 
14. Vassal G, Pondarre C, Cappelli C, 
Terrier-Lacombe MJ, Boland I, Morizet J, 
Benard J, Venuat AM, Ardouin P, Hartmann 
0, Gouyette A: DNA topoisomerase I, a new 
target for the treatment of neuroblastoma. 
Europ J Cancer 33(12):2011-2015, 1997 
15. Choi SH, Tsuchida Y, Yang HW: Oral versus 
intraperitoneal administration of irinotecan in 
the treatment of human neuroblastoma in nude 
mice. Cancer Let 124:15-21, 1998 
16. Kaneko M, Ohakawa H, Iwakawa M: Is ex-
tensive surgery required for treatment of ad-
vanced neuroblastoma'! J Pediatr Surg 32(J 1): 
1616-1619, 1997 
17. Yokoyama 1, lkawa H, Endow M, Fuchimolo 
Y, Watanabe K, Hosoya R, Nishimura K.: The 
role of surgery in advanced neuroblastoma. 
Europ J Pediatr Surg 5(1):23-6, 1995 . 
18. Leavey PJ, Odom LF, Poole M, McNeely L, 
Tyson RW, Haase GM: Intra-operative radi-
ation therapy in pediatric neuroblastoma. Med 
Pediatr Oncol 28(6):424-8, 1997 
19. Lovat PE, Irving H, Annicchiarico-Petruzzelli 
M, Bernassola F, Malcolm AJ, Pearson AD, 
Melino G, Redfern CP: Retinoids in neuro-
blastoma therapy: distinct biological properties 
of 9-cis- and all-trans-retinoic acid. Europ J 
Cancer 33( 12):2075-80, 1997 
20. Wassberg E, Christofferson R: Angiostatic tr-
eatment of neuroblastoma. Europ J Cancer 33 
(12):2020-3, 1997 
21. Mastrangelo R, Tornesello A, Mastrangelo S: 
Role of 13II-metaiodo benzyl guanidine in the 
treatment of neuroblastoma. Med Pediatr Oncol 
31 (J ):22-6, J 998 
22. Castel SV, Melero MC, Garcia RP, Navajas 
GA, Ruiz n, Navarro FS, Garlin VC, Galbe 
SM: Neuroblastoma in children under than 1 
year of age. Anal Espan Pediatr 47(6): 584-90, 
1997 
23. Chamberlain RS, Auinones R, Dinndorf P, 
Movassaghi N, Goodstein M, Newman K: 
Complete surgical resection combined with 
aggressive adjuvant chemotherapy and bone 
marrow transplantation prolongs survival in 
children with advanced neuroblastoma. Ann 
Surg Oncol 2(2):93-100,1995 
24. Wood WG, Tuchman M, Bobison LL, Be-
rnstein M, Lecierc JM, Brisson LC, Brossard 
J, Hill G, Shuster J, Luepker R, Byrne T, 
Weitzman S, Bunin G, Lemieux B: A 
population based study of the usefulness of 
screening for neuroblastoma. Lancet 348(9043): 
1682-7,1996 
- 63 -
